Penserra Capital Management LLC Acquires New Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Penserra Capital Management LLC bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 117,581 shares of the biotechnology company’s stock, valued at approximately $2,350,000. Penserra Capital Management LLC owned approximately 0.05% of ADMA Biologics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ADMA. CANADA LIFE ASSURANCE Co increased its stake in shares of ADMA Biologics by 114.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock worth $357,000 after purchasing an additional 28,832 shares in the last quarter. Shell Asset Management Co. acquired a new position in shares of ADMA Biologics in the first quarter worth $155,000. EntryPoint Capital LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at $31,000. 1832 Asset Management L.P. acquired a new stake in shares of ADMA Biologics during the first quarter valued at $899,000. Finally, Lazard Asset Management LLC increased its position in ADMA Biologics by 5.5% during the 1st quarter. Lazard Asset Management LLC now owns 110,809 shares of the biotechnology company’s stock worth $730,000 after purchasing an additional 5,731 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ADMA shares. Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th.

Insider Activity at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the sale, the chief operating officer now directly owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. This trade represents a 5.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 185,011 shares of company stock worth $3,255,204. 3.70% of the stock is owned by insiders.

ADMA Biologics Trading Up 1.4 %

NASDAQ ADMA opened at $21.47 on Tuesday. The company has a market cap of $5.08 billion, a P/E ratio of 76.68 and a beta of 0.64. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a 50-day moving average of $18.86 and a 200-day moving average of $14.95.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter last year, the firm posted $0.01 earnings per share. As a group, equities analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.